Patupilone (EPO906, Epothilone B)

Catalog No.S1364

Patupilone (EPO906, Epothilone B) Chemical Structure

Molecular Weight(MW): 507.68

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
In DMSO USD 250 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGxENTJvYXSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc4\S1yNjFOwG0> M{m0[XNCVkeHUh?=
human A431 cell NYPLeHlpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2[U0xPiEQvF2= MYHTRW5ITVJ?
human SW1710 cell NEPMepZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\KTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlE1\S1yNTFOwG0> MXPTRW5ITVJ?
human Daoy cell MmrzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjaTo51UW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? NYm2OlNyW0GQR1XS
human BFTC-905 cell MkPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QWVvMEWg{txO NYPwPYV1W0GQR1XS
human A375 cell M{\3[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIq4eI5KdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21[U0xPSEQvF2= MlLFV2FPT0WU
human RKO cell Mn\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk[3TY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkS3[U0xPSEQvF2= Ml7JV2FPT0WU
human KYSE-510 cell NInLSXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGi5XGJKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|OHWtNFUh|ryP M2fzRnNCVkeHUh?=
human HLE cell NIm1cGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGrDTmJKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlZmNTB3IN88US=> M{nidXNCVkeHUh?=
human MCF7 cell NHS1TWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfBTZh[UW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE43PmVvMEWg{txO MnvmV2FPT0WU
human 786-0 cell Mnf4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\MNWlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyKG6P NXnuWmxPW0GQR1XS
human TE-8 cell NYfZUW0xT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNUBvVQ>? MmnTV2FPT0WU
ovarian carcinoma 1A9 cell M{Hxfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoO1TY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3Rib4\hdolidiClYYLjbY5wdWFiMVG5JINmdGxiZ4Lve5Rp NV\ueYhQOTZzM{S5Nlg>
human PANC-03-27 cell NFLKRmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;NUWlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUOyJO69VQ>? MYXTRW5ITVJ?
human VMRC-RCZ cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{n2R2lvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|NjFOwG0> M2DtN3NCVkeHUh?=
human IGROV-1 cell M1TpVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{L6WmlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV4IN88US=> MlvrV2FPT0WU
human MG-63 cell MofSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIK0dmRKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjVizszN M4fpdHNCVkeHUh?=
human SIG-M5 cell NGfSeoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M331eWlvcGmkaYTpc44hd2ZiaIXtZY4hW0mJLV21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjlizszN NHPTe3VUSU6JRWK=
human NCI-H650 cell M3zSOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfFcHJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNzFOwG0> NEnReVJUSU6JRWK=
human PSN1 cell M4LxWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mk[0TY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Mh|ryP MoXCV2FPT0WU
human PA-1 cell M1zHN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWG5[m57UW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzRizszN MoDoV2FPT0WU
KB-8511 cells M1Pvd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV\RT3o{PzJiaB?= MkexR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2{ZYPpd5RidnRiaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvOEWxNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\SluIFnDOVA:OC5zODFOwG0> M1jLdlEyOTN|MEi2
KB-31 cells M{OzZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrZdYE4OiCq MXPDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRidHjlJIdzd3e2aDDv[kBx[WOuaYThfIVtNXOnboPpeIl3\SCqdX3hckBmeGmmZYLtc4llKGOjcnPpco9u[SClZXzsd{BMSi1|MTDifUA2OCCyZYLj[Y51KCh5MjDodkBmgHCxc4Xy[Uk> MkXsNVEyOzNyOE[=
human BHY cell NFXjW5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\sSWlKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk2KG6P MlK1V2FPT0WU
human BB30-HNC cell M3\pXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX[5[mpOUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkCxJO69VQ>? NG\mNoNUSU6JRWK=
human HOS cell NF7MOW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4nKNWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVUh|ryP Mn\XV2FPT0WU
human 639-V cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{HPVmlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQCEQvF2= M2X1S3NCVkeHUh?=
human ES1 cell  M{\IcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvvZXRKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlIyKM7:TR?= NWrRcYo3W0GQR1XS
human TE-15 cell  MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{G2UWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPSEQvF2= NXfjd5RxW0GQR1XS
human LXF-289 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4PyEQvF2= NH:0VXBUSU6JRWK=
human CAL-12T cell Moi2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QSEQvF2= NW[1elVJW0GQR1XS
human T84 cell M3K3PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zvWWlvcGmkaYTpc44hd2ZiaIXtZY4hXDh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOEDPxE1? MlK5V2FPT0WU
human KYSE-450 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm\ETY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUS1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjZ5IN88US=> MYTTRW5ITVJ?
human LCLC-103H cell M1Xoemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjxTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzIH7N MWnTRW5ITVJ?
human NCI-H810 cell M1nKUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnv0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{IN88US=> NGmwRnNUSU6JRWK=
human HUTU-80 cell M1S2bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{Dzc2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> MV\TRW5ITVJ?
human NCI-H460 cell Ml;US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HpbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MzFOwG0> NWfWfGlwW0GQR1XS
human HGC-27 cell M1HEZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M5KM7:TR?= MoLOV2FPT0WU
human HSC-2 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXFb2VoUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ|IH7N MlzpV2FPT0WU
human IA-LM cell NYXDU4d5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX[5UY5nUW6qaXLpeIlwdiCxZjDoeY1idiCLQT3MUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl|IN88US=> MXfTRW5ITVJ?
human HMV-II cell MnrHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HHbmlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN MmXBV2FPT0WU
human COLO-679 cell M3rENmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{fwSmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7NDFOwG0> NFfy[lBUSU6JRWK=
human NCI-H2122 cell M{DCe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjyfWo6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VQ>? NIDCOZNUSU6JRWK=
human CAL-39 cell NVm2TnlVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\xR4tKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDFzIN88US=> Ml:1V2FPT0WU
human SW954 cell NXqzfYNvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1vWSWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ{PiEQvF2= NIWyNXRUSU6JRWK=
human LCLC-97TM1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF[5UHVKdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtPVdVVTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS0OEDPxE1? M3;pN3NCVkeHUh?=
human KYSE-270 cell NHztXGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHRfXR{UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNES1JO69VQ>? MYfTRW5ITVJ?
human NB13 cell M1vJWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoXFTY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60OFch|ryP NVjkc3JwW0GQR1XS
human SK-LMS-1 cell Ml;QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVGyPW4yUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MUXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNkS2JO69VQ>? NYHJV2g1W0GQR1XS
human SW620 cell NF3yPZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7hfmd4UW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR6IN88US=> MmXXV2FPT0WU
human HCT-15 cell NYfwZlI3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDCTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcyPyEQvF2= NXjjb4RsW0GQR1XS
human DU-145 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\4TY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= MXTTRW5ITVJ?
human ST486 cell M1jiNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXzMVnBXUW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJzIN88US=> NEfXVY1USU6JRWK=
human A427 cell NWWybpNJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4L4d2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFI5KM7:TR?= M2KxcnNCVkeHUh?=
human HT-1080 cell NXfVdodHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\yU5BKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2MjFOwG0> NF;vUmdUSU6JRWK=
human NCI-H2009 cell NIjPTWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDZ{IN88US=> MXfTRW5ITVJ?
human SK-LU-1 cell Mmm5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3PiEQvF2= NIG4O29USU6JRWK=
human SCC-4 cell NHHRSI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64O|ch|ryP MWjTRW5ITVJ?
human NCI-H1299 cell MnnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NI\rT4FKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEig{txO MYPTRW5ITVJ?
human NH-12 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkLiTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFkyKM7:TR?= MX3TRW5ITVJ?
human SK-UT-1 cell NWW3N5RsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6OiEQvF2= NVj1Z|U5W0GQR1XS
human Bel7402 NIf5RYRRem:uaX\ldoF1cW:wIHHzd4F6 MVe3NkBp MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUC9NE46KM7:TR?= M2Tzc|IzOzJyM{W0
human A388 cell MnL1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MluyTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OEDPxE1? NHT0[5BUSU6JRWK=
human SW982 cell MnLTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIrNUIxKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QTlizszN NGH2UGJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
+ Expand

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
+ Expand
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Formulation: Dissolved in30% PEG-300
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) supplier | purchase Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) cost | Patupilone (EPO906, Epothilone B) manufacturer | order Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID